Agonistic antibodies offer a compelling therapeutic approach as they can overcome the liabilities of natural ligands and their modified variants. Our DIAGONAL platform combines computational and experimental techniques to rapidly deliver agonist antibodies to any multimeric receptor complex in a single, deterministic campaign. By merging innovative biotechnological techniques with detailed molecular engineering, this study underscores the emerging role of bispecific antibodies as a transformative therapeutic option for managing HHT.

‍